ALVOW
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$0.30
−6.25%Aug 21, 2026, 13:00 UTC
Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for its proposed biosimilars AVT34 (durvalumab) and AVT87 (emicizumab) in the U.S. and selected Asian markets.
Source:Aug 19, 2026, 20:30 UTC
Alvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.
Jul 29, 2026, 13:25 UTC
Alvotech announced that the FDA closed its inspection of its manufacturing facility in Reykjavik, Iceland, with a Voluntary Action Indicated classification.
Jul 1, 2026, 08:00 UTC
Alvotech secured a $75 million term loan facility by amending its existing credit agreement with GoldenTree Asset Management LP and other lenders.
Source:Jun 16, 2026, 03:50 UTC
Alvotech priced a public offering of 22,666,667 ordinary shares at $3.75 per share, raising $152 million.
Jun 8, 2026, 08:00 UTC
Alvotech announced that the FDA accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio.
Jun 5, 2026, 18:35 UTC
Alvotech resubmitted Biologics License Applications (BLAs) to the FDA for its biosimilar candidates AVT05 and AVT06.
Source: